Статья
АЦЕТИЛСАЛИЦИЛОВАЯ КИСЛОТА: ВСЕ ЛИ МЫ О НЕЙ ЗНАЕМ И ПРАВИЛЬНО ЛИ ИСПОЛЬЗУЕМ?
Рассматривают аспекты применения ацетилсалициловой кислоты (АСК) в кардиологической практике. Обсуждают механизмы действия АСК и основные показания для ее применения. Отдельно рассматривают применение АСК при первичной профилактике сердечно-сосудистых заболеваний и ее возможные побочные эффекты. Приводят особенности применения препаратов АСК в конкретных клинических ситуациях, а также обсуждают некоторые плейотропные эффекты.
1. Bokarev I.N., Popova L.V. On the 125th anniversary of acetylsalicylic acid. Rational Pharmacother Card 2011;7(4):492–500. Russian (Бокарев И.Н., Попова Л.В. К 125-летию ацетилсалициловой кислоты. РФК 2011; 7(4): 492–500).
2. Gawaz M., editor. Blood platelets — clinical relevance. Stuttgart: Georg Thieme Verlag; 2010.
3. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71– 86.
4. Antithrombotic Trialist’s Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials. Lancet 2009; 373: 1849–1860.
5. National guidelines for cardiovascular prevention. Kardiovaskulyarnaya Terapiya i Profilaktika 2011; 10 (6) suppl 2: 1–64. Russian (Национальные рекомендации по кардиоваскулярной профилактике. Кардиоваскулярная терапия и профилактика 2011; 10 (6) приложение 2: 1–64).
6. The efficacy and safety of drug therapy for primary and secondary prevention of cardiovascular disease. Recommendations of the All-Russian Society of Cardiology. Rational Pharmacother Card 2011; 5 (suppl): 1–71. Russian (Эффективность и безопасность лекарственной терапии при первичной и вторичной профилактике сердечно-сосудистых заболеваний. Рекомендации ВНОК. РФК 2011; 5 (приложение): 1–71).
7. Guidelines on the management of stable angina pectoris: executive summary. The task force of the management of stable angina pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1334– 1381.
8. National guidelines for antithrombotic therapy in patients with stable manifestations of atherothrombosis. Kardiovaskulyarnaya Terapiya i Profilaktika 2009; 8(6) suppl 6: 1–20. Russian (Национальные рекомендации по антитромботической терапии у больных со стабильными проявлениями атеротромбоза. Кардиоваскулярная терапия и профилактика 2009; 8(6) Приложение 6: 1–20).
9. Tendera M., Aboyans V., Bartelink M.L., et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases. Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology. Eur Heart J 2011;32(22):2851– 906.
10. Dippel D.W. The results of CAPRIE, IST and CAST. Clopidogrel vs. Aspirin in Patients at Risk of Ischemic Events. International Stroke Trial. Chinese Acute Stroke Trial. Thromb Res 1998; 92(1 Suppl 1):S13– S16.
11. Graham I., Atar D., Borch-Johnsen K., et al. European Atherosclerosis Society (EAS). European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Re-habil 2007; Suppl 2: S1–113.
12. Ridker P.M., Cook N.R., Lee I-M. et al. A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women. N Engl J Med 2005;352(13):1293–304.
13. Mosca L., Benjamin E.J., Berra K., et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women 2011 update: a guideline from the American Heart Association. J Am Coll Cardiol 2011; 57(12): 1404–1423.
14. Cleland J.G., Coletta A.P., Yassin A., et al. Clinical trials update from the European Society of Cardiology Meeting 2009: AAA, RELY, PROTECT, ACTIVE-I, European CRT survey, German pre-SCD II registry, and MADIT-CRT. Eur J Heart Fail 2009; 11(12): 1214–1219.
15. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur J Prev Cardiol 2012;19(4):585–667.
16. National guidelines for the diagnosis and treatment of hypertension (fourth revision). Sistemnye Gipertenzii 2010; (3): 5–26. Russian (Национальные рекомендации по диагностике и лечению артериальной гипертонии (четвертый пересмотр). Системные гипертензии 2010; (3): 5–26).
17. Mann J.I., Riccardi G. Evidence-based European guidelines on diet and diabetes. Nutr Metab Cardiovasc Dis 2004; 14(6): 332–333.
18. Buse J.B., Ginsberg H.N., Bakris G.L., et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007; 115(1): 114–126.
19. Soejima H., Morimoto T., Saito Y., Ogawa H. Aspirin for the primary prevention of cardiovascular events in patients with peripheral artery disease or diabetes mellitus. Analyses from the JPAD, POPADAD and AAA trials. Thromb Haemost 2010; 104(6): 1085–1088.
20. Serebruany V.L., Steinhubl S.R., Berger P.B. et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 2005; 95(10): 1218–1222.
21. Yeomans N.D., Lanas A.I., Talley N.J. et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005; 22: 795–801.
22. Abraham N.S., Hartman C., Castillo D. et al. Effectiveness of national provider prescription of PPI gas-troprotection among elderly NSAID users. Am J Gastroenterol 2008; 103: 323–332.
23. Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the Ameri-can College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008; 52(18): 1502–1517.
24. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 13(2): 349–360.
25. Frans Van de Werf, Jeroen Bax, Amadeo Betriu, Carina Blomstrom-Lundqvist et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J 2008; 29: 2909–2945.
26. Hamm C.W., Bassand J.P., Agewall S., et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology. Eur Heart J 2011; 32: 2999–3054.
27. National guidelines for diagnosis and treatment of patients with acute myocardial infarction with ST-segment elevation on ECG. Kardiovaskulyarnaya Terapiya i Profilaktika 2007; 6 (8) prilozhenie: 415– 500. Russian (Национальные рекомендации по диагностике и лечению больных острым инфарктом миокарда с подъемом сегмента ST ЭКГ. Кардиоваскулярная терапия и профилактика 2007; 6 (8) приложение: 415–500).
28. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg 2010; 38 Suppl: S1–S52.
29. Valgimigli M., Campo G., Monti M., Vranckx P. et al. Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 2012; 125 (16): 2015–2026.
30. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124: e 652–e 735.
31. Burger W., Chemnitius J.M., Kneissl G.D.. Rucker G. Low-dose aspirin for secondary cardiovascular prevention—cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation—review and meta-analysis. J Intern Med 2005; 257: 399–414.
32. Spyropoulos A.C., Becker R.C. et.al. The Perioperative Management of antithrombotic American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:299S– 339S.
33. Poldermans D., Bax J.J., Boersma E., et al. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the Еuropean Society of Anaesthesiology (ESA) Eur Heart J 2009; 30: 2769–2812.
34. Camm A.J., Kirchhof P., Lip G.Y.H. et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology. Eur Heart J 2010; 31: 2369—2429.
35. Rothwell P.M., Wilson M., Elwin C.E. et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomized trials. Lancet 2010; 376:1741–1750.
36. Rothwell P.M., Fowkes F.G., Belch J.F., et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377: 31–41.
37. Bardia A., Olson J.E., Vachon C.M., Lazovich D. et al. Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Breast Cancer Res Treat 2011; 126(1): 149–155.
38. Prizment A.E., Folsom A.R., Anderson K.E. Nonsteroidal anti-inflammatory drugs and risk for ovarian and endometrial cancers in the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev 2010; 19(2): 435–442.
39. Martsevich S.Yu., Tolpygina S.N., Boychenko E. S. et al. Comparison of antiplatelet efficacy of original and generic enterosoluble acetylsalicylic acid in patients with high cardiovascular risk. Simple blind crossed randomized controlled study (IKAR). Rational Pharmacother Card 2010;6(6):796–802. Russian (Марцевич С.Ю., Толпыгина С.Н., Бойченко Е.С., и др. Сравнительное изучение дезагрегантной эффективности оригинального и воспроизведенного препарата ацетилсалициловой кислоты в кишечно-растворимой форме у пациентов высокого риска сердечно-сосудистых осложнений. Простое слепое перекрестное рандомизированное контролируемое исследование (ИКАР). РФК 2010; 6(6): 796–802).